China Regenerative Medicine International Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
For the six months, sales was HKD 86.26 million compared to HKD 115.3 million a year ago. Net income was HKD 2.22 million compared to HKD 16.24 million a year ago. Basic earnings per share from continuing operations was HKD 0.00078 compared to HKD 0.00981 a year ago. Basic earnings per share was HKD 0.00078 compared to HKD 0.00569 a year ago.